[HTML][HTML] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
Background No single standard treatment exists for patients with small, node-negative, human
epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of …
epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of …
[HTML][HTML] Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast …
PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment
of patients with small human epidermal growth factor receptor 2 (HER2)–positive breast …
of patients with small human epidermal growth factor receptor 2 (HER2)–positive breast …
Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab
I Shapira, D Andrade, SL Allen… - Arthritis & …, 2012 - Wiley Online Library
Objective Catastrophic antiphospholipid syndrome (CAPS) is characterized by histopathologic
evidence of small vessel thrombosis, dysfunction of multiple organs occurring over a short …
evidence of small vessel thrombosis, dysfunction of multiple organs occurring over a short …
[PDF][PDF] International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature
…, VA Morrison, B Tranchand, I Shapira… - Journal of clinical …, 2007 - academia.edu
The elderly comprise the majority of patients with cancer and are the recipients of the
greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based …
greatest amount of chemotherapy. Unfortunately, there is a lack of data to make evidence-based …
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Background We aimed to report on long-term outcomes of patients with small, node-negative,
HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to …
HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to …
Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity
C Huan, ML Kelly, R Steele, I Shapira… - Nature …, 2006 - nature.com
TFE3 and TFEB are broadly expressed transcription factors related to the transcription factor
Mitf. Although they have been linked to cytokine signaling pathways in nonlymphoid cells, …
Mitf. Although they have been linked to cytokine signaling pathways in nonlymphoid cells, …
[HTML][HTML] Evolving concepts: how diet and the intestinal microbiome act as modulators of breast malignancy
I Shapira, K Sultan, A Lee, E Taioli - International Scholarly Research …, 2013 - hindawi.com
The intestinal microbiome plays an important role in human physiology. Next-generation
sequencing technologies, knockout and gnotobiotic mouse models, fecal transplant data and …
sequencing technologies, knockout and gnotobiotic mouse models, fecal transplant data and …
Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer
Importance Trastuzumab is a life-saving therapy but is associated with symptomatic and
asymptomatic left ventricular ejection fraction (LVEF) decline. We report the cardiac toxic effects …
asymptomatic left ventricular ejection fraction (LVEF) decline. We report the cardiac toxic effects …
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a …
…, RJ Gralla, TP Bradley, SS Ali, I Shapira… - Supportive Care in …, 2012 - Springer
Background The benefit of adding a vena cava filter to anticoagulation in treating cancer
patients with venous thromboembolism remains controversial. We initiated this study as the first …
patients with venous thromboembolism remains controversial. We initiated this study as the first …
Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)
Chemotherapy-related amenorrhea (CRA) is associated with infertility and menopausal
symptoms. Learning how frequently paclitaxel and trastuzumab cause amenorrhea is important. …
symptoms. Learning how frequently paclitaxel and trastuzumab cause amenorrhea is important. …